1. The antibody-drug conjugate comprising an antibody or antigen binding fragment conjugated to monomethylaurostatin E (MMAE), wherein the antibody or fragment contains a heavy chain variable region consisting of an amino acid sequence starting from 20 Q through 143 S of SEQ ID NO: 20 and the variable region of the light chain consisting of the amino acid sequence starting from 23 D to 130 R of the sequence of SEQ ID NO: 22.2. An antibody-drug conjugate containing an antibody or fragment that contains the variable regions of the heavy and light chains of an antibody produced by a hybridoma deposited with the American Type Culture Collection (ATCC) with accession number PTA-8602 conjugated to monomethylaurostatin E (MMAE). 3. The antibody-drug conjugate according to claim 2, wherein the antibody contains the heavy and light chains of an antibody produced by a hybridoma stored in ATCC with accession number PTA-8602.4. The antibody-drug conjugate according to claim 1, wherein the antibody comprises a heavy chain consisting of an amino acid sequence starting from 20 Q to 469 K of the sequence SEQ ID NO: 20, and a light chain consisting of an amino acid sequence starting from 23 D through 236 With the sequence of SEQ ID NO: 22.5. The antibody-drug conjugate of claim 1, wherein the fragment is a Fab, F (ab '), Fv, or sFv fragment. The antibody-drug conjugate of claim 1, wherein the antibody is a fully human antibody. The antibody-drug conjugate of claim 1, wherein the antibody is produced recombinantly. A pharmaceutical composition that contains1. Конъюгат антитело-лекарственное средство, содержащий антитело или антигенсвязывающий фрагмент конъюгированный с монометилауростатином Е (ММАЕ), где антитело или фрагмент содержат вариабельную область тяжелой цепи, состоящую из аминокислотной последовательности, начиная с 20 Q по 143 S последовательности SEQ ID NO:20 и вариабельную область легкой цепи, состоящую из аминокислотной последовательности, начиная с 23 D по 130 R послед
